Prothazin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prothazin

Property Description
Active ingredient Promethazine (typically as the hydrochloride salt)
Forms Tablet, Syrup, Suppository, Injectable Solution
Pharmacological class First-generation Antihistamine; Phenothiazine Derivative
Common purpose Antiallergic, Sedative, and Antiemetic effects
Origin Synthetic chemical compound

What Type of Medicine Is Prothazin (Promethazine)?

Prothazin is the medicinal product containing the active substance Promethazine, which is structurally defined as a synthetic phenothiazine derivative and functionally classified as a first-generation antihistamine. Promethazine crosses the blood-brain barrier, a characteristic responsible for its central nervous system activity, distinguishing it from newer, non-sedating agents. It is classified as both an antihistamine and an antiemetic, possessing potent H1 blocking and anticholinergic activities. This profile allows the drug to manage allergy symptoms while also influencing nerve signals in the brain. It is formulated as the Promethazine hydrochloride salt and is primarily available as a single-ingredient product, though it may be found in combination formulations, often with antitussive agents.

Primary Purpose and Available Forms of Prothazin

The general purpose of this medicine is to leverage its broad action across multiple receptor systems to provide antiallergic, pronounced sedative, and strong antiemetic effects. Promethazine falls under the ATC category R06AD02, as an antihistamine with significant secondary effects on the central nervous system. This multi-receptor antagonism is used for the management of nausea and vomiting, such as those associated with motion sickness, and for promoting rest. To ensure flexibility for patient needs, Promethazine is supplied in several dosage forms, including tablets and syrups for oral ingestion, suppositories for rectal administration, and injectable solutions for parenteral delivery. This variety of preparations enables use across a wide range of general application scenarios.

Regulatory References

  1. Promethazine: MedlinePlus Drug Information
  2. Promethazine - StatPearls - NCBI Bookshelf

What side effects are possible with Prothazin?

Possible Side Effects and Safety Information

Official regulatory documents characterize the safety profile of Prothazin (promethazine) primarily through its effects on the Central Nervous System (CNS) and specific age-related restrictions. The medicine is absolutely contraindicated in children younger than two years of age due to the potential for fatal respiratory depression. This is a non-negotiable safety restriction.

Common and Expected Adverse Reactions

The most frequently reported adverse effect is marked drowsiness or sedation, which is dose-related. Other common reactions involve the CNS and include dizziness, incoordination, confusion, and impaired mental and physical abilities. Anticholinergic effects such as dry mouth, blurred vision, and urinary retention are also commonly documented.

Serious and Clinically Significant Adverse Reactions

Serious, though rare, adverse events involve several body systems. These include blood dyscrasias such as agranulocytosis (a severe reduction in white blood cells) and leukopenia. Cardiovascular effects such as hypotension (low blood pressure) may also occur. Neurological risks include seizures and the rare but life-threatening Neuroleptic Malignant Syndrome (NMS), a severe reaction characterized by high fever, muscle rigidity, and altered mental status.

Safety Restrictions and Monitoring

Caution is advised when administering the medicine to the elderly due to their increased susceptibility to confusion and anticholinergic effects. When administered by injection, severe localized reactions, including tissue damage and gangrene, have been documented, leading to the strict regulatory restriction that the injectable form must not be administered intra-arterially or subcutaneously.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with Promethazine (Prothazin) as a potentially severe event, and immediate medical action is required. Seek immediate medical attention for any suspected overdose or ingestion of excessive amounts. Contact emergency services (e.g., 911 or the Poison Help hotline) without delay.

Overdose Presentation (Officially Documented) Associated Risks
CNS Effects: Drowsiness, coma, agitation, confusion, seizures, hallucinations, unsteadiness, or restlessness. Respiratory Depression: Potentially fatal respiratory depression, sudden death, and apnea are reported, especially in pediatric patients.
Autonomic/Cardiovascular Effects: Rapid heartbeat (tachycardia), low blood pressure (hypotension), and cardiac dysrhythmias. Neuroleptic Malignant Syndrome (NMS): A potentially fatal complex characterized by fever, muscle rigidity, and altered mental status.

Management is strictly symptomatic and supportive treatment, as no specific antidote is known for Promethazine overdose. Hospital-level observation, including monitoring of vital signs and ECG (heart tracing), is mandated. Note that Epinephrine should NOT be used to treat hypotension in this context, as it may worsen the condition. Population-specific warnings advise against use in pediatric patients under two years of age due to the risk of fatal respiratory depression.

Therapeutic Uses of Prothazin

What Prothazin Treats: Main Uses and Benefits

Prothazin is used in the context of supporting the management of various symptoms and conditions where specific therapeutic action is needed. The compound is applied to help manage allergic manifestations, which may include reducing symptoms associated with seasonal allergic rhinitis (hay fever), managing skin reactions like hives (urticaria), and addressing other acute allergic events. Additionally, Prothazin has therapeutic utility for short-term relief of sleep disturbance in specific clinical scenarios, helping patients achieve necessary rest. It may also be used to support the management of nausea and vomiting associated with motion sensitivity.

The overall benefit of Prothazin is its potential to mitigate these challenging symptoms, thereby supporting patient comfort and functional status in the short term.

Quick Fact: Relief for Allergic Symptoms and Sleep Disturbance

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Promethazine

The eligibility for Promethazine (Prothazin) use is strictly defined by regulatory documents, particularly concerning age, respiratory status, and neurological health.

Eligibility Classification Population Group Regulatory Basis
Absolute Contraindication Pediatric patients less than 2 years of age Risk of fatal respiratory depression
Absolute Contraindication Patients in a comatose state or with severe CNS depression Central Nervous System effects
Absolute Contraindication Individuals with known hypersensitivity to promethazine or other phenothiazines Allergic reaction risk
Absolute Contraindication Treatment of lower respiratory tract symptoms, including asthma Respiratory risk

Age-Related Eligibility Rules: The medicine is generally permitted for use in adults. For children 2 years of age and older, caution must be exercised, and the lowest effective dose should be used. Older adults also require cautious use, often starting at the low end of the dosing range, due to a higher potential for side effects and age-related organ changes.

Condition-Specific Eligibility Rules: Use is restricted or requires caution in persons with conditions such as impaired liver function, narrow-angle glaucoma, prostatic hypertrophy, cardiovascular disease, or pre-existing seizure disorders. Promethazine should also be avoided in children whose symptoms suggest Reye's syndrome.

Pregnancy and Lactation: Promethazine is generally classified as Pregnancy Category C, meaning use is conditional: permitted only if the potential benefit justifies the potential risk to the fetus. The drug is excreted into human milk, and its use is typically not recommended for breastfeeding mothers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Prothazin (Promethazine) has officially documented interaction patterns primarily involving additive central nervous system (CNS) depression and anticholinergic potentiation, as detailed in regulatory prescribing information.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally restricted, or contraindicated, including within 14 days of MAOI therapy, due to the risk of intensifying CNS depressant and anticholinergic effects.

Pharmacodynamic Interactions

Concurrent use with Alcohol (Ethanol) or other CNS Depressants (such as opioids, sedatives, or general anesthetics) may increase, prolong, or intensify the sedative action of Promethazine. Combining it with other Anticholinergic Agents potentiates the effects, raising the risk of severe anticholinergic outcomes. A specific interaction involves Epinephrine (Adrenaline), where Promethazine may block the alpha adrenoceptor agonist effects, leading to paradoxical severe hypotension.

Pharmacokinetic and Transporter Effects

Interactions involving metabolism inhibition are documented, such as the co-administration with Beta Blockers (e.g., Propranolol), which can result in increased plasma concentrations of both agents. Promethazine also shows a transporter-mediated effect by inhibiting the neuronal uptake of Guanethidine, thereby reducing its antihypertensive effect.

Timing-Based Interaction Rules

Promethazine is recommended to be discontinued at least 72 hours before allergen skin testing to prevent diagnostic interference and false negative results.

Mechanism of Action

Central and Peripheral Pathway Modulation

The active substance, Promethazine, functions as a competitive antagonist at multiple G-protein coupled receptors. Its primary mechanism involves blocking the Histamine mathbfH1 receptor both centrally and peripherally. The molecule readily crosses the blood-brain barrier, allowing it to reduce histaminergic signaling in the central nervous system, initiating a cascade that results in a state of decreased neuronal excitability. The peripheral H1 antagonism limits the actions of histamine, contributing to a physiological reduction of histamine-mediated vascular leakage.

Multi-Receptor Suppression of Reflexes

The antiemetic mechanism relies on a simultaneous antagonism of Dopamine mathbfD2 receptors in the Chemoreceptor Trigger Zone (CTZ) and Muscarinic Acetylcholine receptors in the Vestibular Nuclei. This coordinated multi-receptor suppression stabilizes the medullary Vomiting Center, leading to the suppression of the neural output that coordinates the emetic reflex. Additionally, Promethazine inhibits Voltage-Gated Sodium (mathbfNa^+) Channels in nerve membranes, preventing action potential transmission in sensory neurons, which is distinct from its receptor antagonism.

Dosage and Administration Information

How Prothazin is Used: Administration Guidelines

Promethazine (Prothazin) is administered via multiple routes, with available forms including tablets, syrup for oral ingestion, suppositories for rectal use, and injectable solutions for parenteral delivery. The parenteral route involves either deep intramuscular (IM) injection, which is often the preferred method, or controlled intravenous (IV) infusion. A strict procedural instruction is that the medicine must never be administered via the subcutaneous or intra-arterial routes.

Standard adult regimens are determined by the intended pattern of use. For routine administration, such as short-term sedation or allergy maintenance, a dose of 25 mg is commonly taken once daily at bedtime. For acute, as-needed dosing—such as treating nausea and vomiting—the initial dose is typically 12.5 mg to 25 mg, which may be repeated every four to six hours as required. The maximum single dose is 50 mg across most indications, with the total daily amount limited to 100 mg in specific contexts.

Key instructions for proper use include taking oral forms with food, water, or milk to reduce potential gastrointestinal upset. If using the syrup form, an accurate measuring device must be employed to ensure dose precision. For the IV route, the solution must be diluted, and the administration rate must not exceed 25 mg/minute. A crucial age-related instruction is the absolute prohibition of the medicine's use in children under two years of age; for older children, dosing must adhere to the principle of using the lowest effective quantity.

Recent Clinical Evidence

Prothazin: Recent Clinical Evidence

Research on Prothazin (promethazine) focuses primarily on its established uses, particularly its function as a first-generation H1 receptor antagonist. Studies continue to investigate its effects related to allergic symptoms, nausea, vomiting, and sedation.


Evaluating the Drug's Effects

Research evaluated the drug’s potential mechanism of action, which involves blocking histamine H1 receptors and acting as an antagonist at several other brain receptors. This multi-receptor activity is thought to underlie its diverse observed effects, including antiemetic and sedative properties.

  • Acute Symptom Studies: Clinical trials have investigated the drug’s effect on acute symptoms, such as post-operative nausea and vomiting. One comparative study reported that low-dose intravenous Prothazin was associated with similar rates of symptom change at one and three hours when compared against a common antiemetic standard.
  • Sedation and Apprehension: Research has consistently examined the use of Prothazin to relieve apprehension and produce a light, easily aroused sleep, especially in pre-operative or in-hospital settings. Its sedative effect is a frequently observed outcome in studies across various indications.

Safety and Tolerability Profiles

Observed Side Effects in Trials

Type of Effect Frequently Observed Events
Central Nervous System Drowsiness, sedation, dizziness
Anticholinergic Effects Dry mouth, blurred vision, constipation
  • Tolerability: Side effects were generally reported as minor in the short-term studies, with sedation being the most common finding. This central nervous system effect has been explored as a factor that may influence treatment continuation rates.
  • Specific Populations: Studies did not identify significant safety concerns within the populations examined. However, it is a standard safety practice to discuss potential drug interactions and suitability for individuals with underlying conditions, such as those impacting the respiratory or renal systems, with a healthcare provider.

Frequently Asked Questions (FAQ)

Common questions about Prothazin (FAQ)

Q: How quickly does Prothazin start working for allergies?

A: Official regulatory documents indicate that the active ingredient in Prothazin is well-absorbed after being taken orally. Because of this, the medication is described as being well-absorbed, with effects typically starting within the duration of action listed in the labeling, which is generally four to six hours.


Q: Can I take Prothazin for motion sickness on a long trip?

A: The official indications for Prothazin include the prevention and control of nausea and vomiting, such as those associated with motion sickness. Timing for use in relation to travel should follow the specific administration instructions provided in the product’s official prescribing information.


Q: Is it normal to feel dizzy the morning after taking Prothazin?

A: Dizziness and drowsiness are common side effects reported in the official product labeling. Since Prothazin can cause impaired physical and mental abilities, these effects may linger into the next day. Official warnings caution that the drug’s effects, such as impaired abilities, may persist, which is relevant when considering activities that require full alertness.


Q: What are the signs of a serious reaction to Prothazin?

A: Serious adverse reactions, though rare, have been documented in regulatory information. These include signs of Neuroleptic Malignant Syndrome (NMS), which can involve high fever, very stiff muscles, and altered mental status. Signs of potential blood problems, like a severe reduction in white blood cells (leukopenia), have also been reported.


Q: Are there any common foods or drinks that interact with Prothazin?

A: The official product label advises taking the oral forms of Prothazin with food, water, or milk. This is specifically recommended to help reduce the potential for stomach upset. Outside of alcohol, regulatory texts do not routinely cite specific interactions with common non-alcoholic foods or drinks.


Q: Does Prothazin interact with common painkillers like ibuprofen?

A: Prothazin has the potential to increase, prolong, or intensify the sedative actions of other medicines that depress the central nervous system. However, specific non-opioid, over-the-counter painkillers like ibuprofen are not typically listed in the drug interactions section of the regulatory information.


Q: Does Prothazin interact with supplements like melatonin or St. John's Wort?

A: Official information confirms that Prothazin interacts with other CNS depressants and medications with anticholinergic properties. However, specific herbals or dietary supplements like melatonin or St. John's Wort are generally not individually addressed in the drug's formal prescribing information.


Q: What is the difference in effect between Prothazin liquid and tablets?

A: The active ingredient, promethazine hydrochloride, remains the same across both the oral tablet and oral solution (syrup) forms. Regulatory information generally does not provide a specific comparison of the onset or duration differences between the oral liquid and tablet forms.


Q: Can Prothazin cause nightmares or strange dreams?

A: Yes, regulatory adverse reaction data notes that strange dreams and vivid dreams, as well as nightmares, have been reported in connection with the use of Promethazine. These effects are sometimes noted as a manifestation of relative overdosage, particularly in younger patients.


Q: Is there a risk of becoming dependent on Prothazin for sleep?

A: Regulatory literature emphasizes the drug's potential for misuse and abuse, particularly when it is combined with other substances like certain opioids. Abuse reports are documented, often in combination with other drugs, which raises a regulatory concern regarding misuse and potential dependence.


Q: What is the main difference between Prothazin and other prescription allergy medicines?

A: Promethazine is officially classified as a first-generation antihistamine. It is primarily distinguished from newer prescription allergy medicines by its potent ability to cross the blood-brain barrier. This characteristic is what gives it its significant sedative and central nervous system effects, in addition to treating allergies.


Q: Are there specific medical conditions that mean I should not use Prothazin?

A: Yes, Prothazin is absolutely contraindicated (should never be used) in patients under two years of age and in individuals in a comatose state. Additionally, those with a known hypersensitivity or allergy to promethazine or other drugs in the phenothiazine class should not use this medicine.


Q: Does Prothazin affect blood pressure?

A: The regulatory safety profile indicates that Prothazin can cause hypotension, which is low blood pressure, as a serious but rare adverse reaction. Official prescribing information also warns that the drug can potentially reverse the desired effect of the blood-pressure raising medicine Epinephrine.


Q: Can Prothazin cause restlessness instead of drowsiness in some people?

A: Yes. Official regulatory warnings report that restlessness and motor hyperactivity have been observed as adverse reactions. These effects are sometimes noted as a paradoxical reaction, particularly in children following a single dose or when the drug is used with certain narcotics.


Q: Is Prothazin effective for anxiety or just for sleep related to anxiety?

A: The drug is officially indicated for use in settings like pre-operative care to alleviate apprehension and to induce light sedation (sleep). It is not specifically indicated for the treatment of generalized anxiety disorders, but rather for short-term apprehension and sedation.


Q: Can Prothazin cause sensitivity to sunlight?

A: Yes. The official adverse reactions section of the product labeling includes reports of photosensitivity, which means increased or unusual sensitivity to sunlight. This is listed as a potential allergic reaction associated with the use of Promethazine.


Q: Is Prothazin a controlled substance?

A: Promethazine itself, when formulated as a single ingredient, is generally not classified as a controlled substance in the U.S. However, certain cough or pain preparations that combine Promethazine with other drugs, such as codeine, are officially classified as Schedule V controlled substances.


Q: Are there generic versions of Prothazin available?

A: Yes. The active ingredient, Promethazine hydrochloride, is widely listed in regulatory product databases. Because it is an older drug, it is commonly available as a generic medicine in multiple dosage forms, including oral tablets.


Q: Is it possible to develop a tolerance to the sedative effects of Prothazin?

A: While the regulatory label heavily emphasizes the drug's potent sedative effect, tolerance—where the drug's effect lessens over time—is not explicitly listed as an adverse reaction. However, it is a general possibility associated with long-term use of many medications that depress the central nervous system.


Q: Can Prothazin make you feel groggy or 'hungover'?

A: Official safety information reports common central nervous system effects such as marked drowsiness, dizziness, and confusion. These reported effects are consistent with what people often describe using non-medical terms like 'groggy' or 'hungover' the day after taking the medication.


Q: Can I take Prothazin if I have glaucoma?

A: Official warnings state that Prothazin should be used with caution in individuals who have certain pre-existing conditions, including narrow-angle glaucoma. This is because the drug has anticholinergic properties which can worsen conditions like this.


Q: Does Prothazin have any known effects on laboratory blood tests?

A: Yes. The official labeling confirms that Promethazine can interfere with certain diagnostic tests, which may lead to inaccurate results. This includes some immunological pregnancy tests, which might show false-positive or false-negative readings, and the glucose tolerance test.

How should Prothazin be stored and disposed of?

How to Store and Dispose of Promethazine Hydrochloride (Prothazin)

Promethazine must be stored strictly according to official regulatory requirements to maintain its integrity and stability.

Storage Requirements

Condition Requirement
Temperature Controlled Room Temperature: between 20 C and 25 C (68 F and 77 F).
Protection Must be protected from light and stored in its original container.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired Promethazine must be disposed of according to local requirements and authorized take-back programs. It must not be disposed of by flushing it down the toilet or pouring it into a drain, as directed by official environmental guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prothazin found in:

A-Z Index: